NEW YORK (GenomeWeb) – BioMérieux is collaborating with Bioaster, a French accelerator of microbiology technology innovation; ESPCI, the College of Physics and Industrial Chemistry of the city of Paris; GSK; HCL, the Hospices Civils de Lyon; and Sanofi to identify and validate new biomarkers aimed at diagnosing patients that present with high risk of sepsis.